You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-NFkB p105 / p50 antibodySee all NFkB p105 / p50 primary antibodies ...
  • Description
    Rabbit polyclonal to NFkB p105 / p50
  • SpecificityRecognition is at the N-terminus. This antibody will "supershift " NFkB complexes containing the human p50 subunit. Control peptide ab7550 will compete only with the specific reaction of antiserum with Human NFkB p50 (NFKB1).
  • Tested applicationsIHC-P, ELISA, Gel supershift assays, IP, WB more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide: AEDDPYLGRFEQMF conjugated to KLH, corresponding to N terminal amino acids 2-15 of Human NFkB p50.

  • General notesNFkB is formed as a homo- or hetero-dimer. Subunits include p50 (NFkB1), p65 (RelA), c-Rel, RelB and p52 (NFkB2). The classic NFkB form exists as a p50-p65 heterodimer and predominates in many cell types. Many of the possible combinatorial forms of homo- and heterodimers have been identified and growing evidence indicates that different forms of NFkB have different functions in cells. Nuclear translocation of NFkB is confirmed by the use of electrophorectic mobility shift assays or by immunoblotting with nuclear extracts. The subunit composition of NFkB is confirmed by the use of antibodies that "supershift" the DNA/protein complex.

Properties

Applications

Our Abpromise guarantee covers the use of ab7549 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-P IHC-P: Use at an assay dependent dilution. PubMed: 17220207
ELISA ELISA: Use at an assay dependent dilution.
Gel supershift assays GSA: Use at an assay dependent dilution. Use at a concentration of 0.5 - 1.0 µl per assay Control Peptide ab7550 1.0 ul per ul antiserum.
IP IP: Use at an assay dependent dilution.
WB WB: 1/1000. Detects a band of approximately 50 kDa (predicted molecular weight: 50 kDa).

Target

  • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
  • Sequence similaritiesContains 7 ANK repeats.
    Contains 1 death domain.
    Contains 1 RHD (Rel-like) domain.
  • DomainThe C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
    Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
  • Post-translational
    modifications
    While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
    Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
    Polyubiquitination seems to allow p105 processing.
    S-nitrosylation of Cys-61 affects DNA binding.
  • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
  • Target information above from: UniProt accession P19838 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      DKFZp686C01211 antibodyDNA binding factor KBF1 antibodyDNA binding factor KBF1 EBP1 antibody
      DNA binding factor KBF1 EBP1 antibodyDNA-binding factor KBF1 antibodyEBP 1 antibodyEBP-1 antibodyEBP1 antibodyKBF1 antibodyMGC54151 antibodyNF kappa B antibodyNF kappabeta antibodyNF kB1 antibodyNFKB 1 antibodyNFKB p105 antibodyNFKB p50 antibodyNFKB1 antibodyNFKB1_HUMAN antibodyNuclear factor kappa B DNA binding subunit antibodyNuclear factor NF kappa B p105 subunit antibodyNuclear factor NF kappa B p50 subunit antibodyNuclear factor NF-kappa-B p50 subunit antibodyNuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibodyNuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibodyp84/NF-kappa-B1 p98 antibody
    see all

References for Anti-NFkB p105 / p50 antibody (ab7549)

This product has been referenced in:
  • Huang Y & Ratovitski EA Phosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradation. J Biol Chem 285:41422-31 (2010). WB ; Human . Read more (PubMed: 20959455) »
  • Jenkins GJ  et al. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol 60:1232-7 (2007). IHC-P ; Human . Read more (PubMed: 17220207) »

See all 2 Publications for this product

Product Wall

Displaying 1 - 3 of 3 results for Abreviews and Q&A

Thank you for your enquiry. The immunogen sequence used for this product was: AED DPY LGR FEQ MF

This antibody has not yet been tested on rabbit tissue.

This antibody doesn't react with the analogous protein in mouse.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"